Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study

Table 1 Clinical characteristics of the patients in this study and of those in the report by Liu and colleagues [7]

Variable	This study	Data from [7]	Pvalue
Age in years, mean ± SD	54.2 ± 13.1	57 ± 13.5	0.06
Age in years at diagnosis, mean ± SD	46.2 ± 13.5	47 ± 15	0.3
Women, percentage	84.8	75	0.06
Disease duration in years, mean ± SD	7.8 ± 6.6	8 ± 8	0.4
Current smokers, percentage^a	9.1	15	0.3
Ever smokers, percentage^a	25.0
Rheumatoid factor-positive, percentage	68.9	83.8	0.01
Anti-CCP-positive, percentage^a	86.3	61.9	0.0001
Shared epitope-positive, percentage^a	58.3
Antinuclear antibody-positive, percentage^a	29.8
HAQ at baseline, mean ± SD	1.4 ± 0.7	1.1 ± 0.6	0.0005
DAS28 at baseline, mean ± SD	5.6 ± 1.2	5.2 ± 0.8	0.002
DAS28 ≥ 5.1, percentage	70.2
3.2 ≤ DAS28 > 5.1, percentage	26.5
DAS28 at 12 to 16 weeks, mean ± SD	3.6 ± 1.4	3.7 ± 1.3	0.2
DAS28 at 6 months, mean ± SD	3.5 ± 1.4
Good responders at 12 to 16 weeks, percentage	40.4	34.8	0.6
Non-responders at 12 to 16 weeks, percentage	22.5	25.8	0.6
Good responders at 6 months, percentage	43.7
Non-responders at 6 months, percentage	21.8
Anti-tumor necrosis factor drug
Infliximab, number	101	32	0.01
Etanercept, number	35	39	0.02
Adalimumab, number	15	18	0.05

^aData were available for 102 patients for anti-cyclic citrullinated peptide (CCP) antibodies, antinuclear antibody, and shared epitope and for 88 patients for smoking habits. DAS28, disease activity score using 28 joint counts; HAQ, health assessment questionnaire; SD, standard deviation.

ISSN: 1478-6362